PTO/SB/25 (05-03)

Approved for use through 4/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A PENDING SECOND APPLICATION	

In re Application of: Ales Franc et al.

Application No.: 10/549,296

Filed: September 15, 2005

FIG. PHARMACEUTICAL COMPOSITION CONTAINING PLATINUM COMPLEX AS ACTIVE SUB-

The owner*, Pliva-Lachema A.S., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 164 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Number 12305322

filed on 03-12-2009 of any patent on the pending second application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee. Its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutionly ideclaimed in whole or terminally disclaimed and 73 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutor term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1.	\Box	For submissions on behalf of an organization (e.g., corporation, partnership, etc.), the undersigned is empowered to act on behalf of the organization.	university, g	overnment a	gency
	ш	etc.) the undersigned is empowered to act on behalf of the organization.			

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuad thereon.

2. X The undersigned is an attorney or agent of record.

Signatura Data

Nader A Ahadir

Typed or printed name

845-359-7700

Telephone Number

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This policition of information is required by 37 CFR 1.31. The information is required to obtain or retain a benefit by the public which is it to life (and by the USPTO) to process) an application. Confidentially is governed by \$5 U.S.C. 1.22 and \$3.7 CFR 1.41. This collection is estimated to take 12 minutes to complete, including quite-inity, preparing, and susmitting the controlled application form to the USPTO. Time will very depending upon the individual case. Any comments on the manuant of time by an enquire to complete this form and/or suggestions for reducing fisite burden, should be sent to the Clief information CFM. P.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1459, Alexandria, V.A. 2331-4450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND (TO Commissioner for Patents, P.O. Box 456). Alexandria, V.A. 2331-450.